1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial
Claudia M. Denkinger(Heidelberg University), Carsten Müller‐Tidow(Heidelberg University), Michaël Schmitt(Heidelberg University), Michael Kreuter(Johannes Gutenberg University Mainz), Katharina Kriegsmann(Getrag (Germany)), Julia Gall(German Cancer Research Center), Johannes Krisam(University Hospital Heidelberg), Ralf Bartenschlager(German Cancer Research Center), Anke Morgner(Klinikum Chemnitz), Maike Janssen(Heidelberg University), Cihan Celik(Klinikum Darmstadt), Felix Herth(Heidelberg University), Martin Bornhäuser(Technische Universität Dresden), Lukas Baumann(Statistics Austria), Carl Christoph Schimanski(Johannes Gutenberg University Mainz), Hans‐Georg Kräusslich(Heidelberg University), Lars Bullinger(Stanford University), Stefan Meurer, Olaf Hopfer(Goethe University Frankfurt), Ulrike Schäkel(Health First), Marylyn M. Addo(Universität Hamburg), Michael Kiehl(Klinikum Frankfurt Höchst), Richard F. Schlenk(German Cancer Research Center), Uta Merle(Heidelberg University), Bernd Hertenstein(San Antonio College), Phil‐Robin Tepasse(University Hospital Münster), Mathias Hänel(Klinikum Chemnitz), Nael Alakel(University Hospital Carl Gustav Carus), Niels Halama(German Cancer Research Center), Stefan Schmiedel(Universität Hamburg), Maria J. G. T. Vehreschild(Goethe University Frankfurt), Jennifer Klemmer(Heidelberg University), Winfried V. Kern(University Medical Center Freiburg), Jens Schrezenmeier(Charité - Universitätsmedizin Berlin), Margarida Souto‐Carneiro(Heidelberg University), Hanns‐Martin Lorenz, Jacek Stermann(Heidelberg University), Patrick Stelmach(German Cancer Research Center), Oliver Witzke(Essen University Hospital), Mohammad-Amen Wattad, Bárbara Müller(Heidelberg University), Martina Gronkowski(Heidelberg University), Stefan Weber(Heidelberg University), Markus A. Weigand(Heidelberg University), Anita Schmitt(Heidelberg University), Albrecht Leo, Timo Wolf(Goethe University Frankfurt), Matthias Ruhe(Herford Hospital), Thorsten Pohle(Herford Hospital)
Cited by 0
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k